Navigation Links
Biopure Reports on Meeting with the FDA
Date:9/6/2007

CAMBRIDGE, Mass., Sept. 6 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR) today announced that it had recently met with the FDA to discuss the compassionate use protocol submitted by the company in July. At the FDA's suggestion, the company intends to submit a protocol for a Phase 2 randomized trial for the treatment of autoimmune hemolytic anemia and other forms of hemolytic anemia, including alloantibody anemia but excluding sickle cell anemia. Hemopure has been used previously, on a compassionate use basis, to treat patients with these conditions.

The proposed patient group was included in the compassionate use protocol previously proposed to the FDA. A study protocol for the treatment of autoimmune hemolytic anemia and other forms of hemolytic anemia would be in place of that compassionate use protocol. Biopure may continue to work with the FDA on compassionate use cases through single patient INDs that are requested from treating physicians.

Autoimmune hemolytic anemia is a group of disorders characterized by a malfunction of the immune system that produces antibodies to the patient's red blood cells attacking them as if they were substances foreign to the body. This group of disorders is uncommon, can occur at any age and affects women more often than men.

Biopure Corporation

Biopure Corporation develops, manufactures and markets pharmaceuticals, called oxygen therapeutics, that are intravenously administered to deliver oxygen to the body's tissues. Hemopure(R) [hemoglobin glutamer - 250 (bovine)], or HBOC-201, is approved for sale in South Africa for the treatment of surgical patients who are acutely anemic. Biopure has applied in the United Kingdom for regulatory approval o
'/>"/>

SOURCE Biopure Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... SAN DIEGO , May 6, 2015  Mirati ... financial results for the first quarter ended March 31, ... programs. "We continue to make progress ... M. Baum , M.D., Ph.D., president and CEO, Mirati. ... at the upcoming American Society of Clinical Oncology meeting ...
(Date:5/6/2015)... -- Delcath Systems, Inc. (NASDAQ: DCTH ), a ... with an emphasis on the treatment of primary and ... months ended March 31, 2015.  Highlights ... , Achieved quarterly product revenue of $0.44 million, an ... quarter of 2014; , Activated a prospective patient ...
(Date:5/6/2015)... and influencers across North America have ... melanoma prevention begins with parents-encouraging everyone to create a #newfamilyrule ... , and parenting author Alyson Schafer are among ... to share this poignant video message: Click ... Melanoma Fund (DCMF)-producers of the viral video Dear ...
Breaking Medicine Technology:Mirati Therapeutics Reports First Quarter 2015 Financial Results and Provides Business Update 2Mirati Therapeutics Reports First Quarter 2015 Financial Results and Provides Business Update 3Mirati Therapeutics Reports First Quarter 2015 Financial Results and Provides Business Update 4Mirati Therapeutics Reports First Quarter 2015 Financial Results and Provides Business Update 5Delcath Reports 2015 First Quarter Financial Results 2Delcath Reports 2015 First Quarter Financial Results 3Delcath Reports 2015 First Quarter Financial Results 4Delcath Reports 2015 First Quarter Financial Results 5Delcath Reports 2015 First Quarter Financial Results 6Delcath Reports 2015 First Quarter Financial Results 7Delcath Reports 2015 First Quarter Financial Results 8Celebrities Tweet Their Support of Melanoma Awareness Month and #newfamilyrule 2
... MAQUET Cardiovascular LLC today announced the launch ... VASOSHIELD Pressure Controlling Syringe for use during Coronary Artery ... "flushing" pressure and controls vessel distension when harvested grafts ... Avoiding excessive pressure and limiting distension help maintain internal ...
... N.J. , May 3 Covance Inc. (NYSE: CVD ... Health Care Conference on Tuesday, May 4, 2010 at 1:30 ... www.covance.com .  In order to register and download any necessary software, please ... , Covance, ...
Cached Medicine Technology:MAQUET Cardiovascular Introduces New VASOSHIELD Pressure Controlling Syringe to Help Preserve Graft Integrity for Coronary Artery Bypass Surgery Patients 2MAQUET Cardiovascular Introduces New VASOSHIELD Pressure Controlling Syringe to Help Preserve Graft Integrity for Coronary Artery Bypass Surgery Patients 3MAQUET Cardiovascular Introduces New VASOSHIELD Pressure Controlling Syringe to Help Preserve Graft Integrity for Coronary Artery Bypass Surgery Patients 4
(Date:5/6/2015)... (PRWEB) May 06, 2015 Qushanna Doby (20) ... a nearby drug treatment center in Florida while under the ... May 4th. New surveillance tapes released by CBS4’s Peter D’Oench ... her baby. Doby’s child is around one year old. The ... and shivering outside was not named. The residents polled by ...
(Date:5/6/2015)... (PRWEB) May 06, 2015 Corporate ... behalf of MEBC, an Alliance Award for excellence ... during FOCUS 2015, JDA’s annual user conference which ... retail and wholesale distribution sectors. This award recognizes ... are receiving services that advance their supply chain ...
(Date:5/6/2015)... May 06, 2015 The Canton Group is ... for the 6th annual charity softball game. The event ... & T Bank Stadium. Past years guests include Joe Flacco, ... are still on sale if you are interested ... local non-profit organizations, such as SOAR Baltimore and ...
(Date:5/6/2015)... Fla. (PRWEB) May 06, 2015 ... Institute are the first in north Florida and ... technology is the latest innovation in total hip ... highly advanced, surgeon-controlled robotic arm that enables the ... Medical Center Jacksonville has offered MAKOplasty® partial knee ...
(Date:5/6/2015)... (PRWEB) May 06, 2015 TMG Health, ... to the Medicare Advantage, Medicare Part D and Managed ... Continuity and Resilience Team category at the BCI North ... Institute to recognize the outstanding contribution of business continuity ... North America Region, including the USA and Canada. The ...
Breaking Medicine News(10 mins):Health News:Flakka Induced Mother Abandons Baby, found by Florida Drug Treatment Center; New Video Released 2Health News:MEBC Receives Award for Consulting Excellence in Retail 2Health News:The Canton Group Sponsors Ravens Charity Softball Event 2Health News:The Canton Group Sponsors Ravens Charity Softball Event 3Health News:Baptist Health and Jacksonville Orthopaedic Institute Offering MAKOplasty® Total Hip Replacement 2Health News:Baptist Health and Jacksonville Orthopaedic Institute Offering MAKOplasty® Total Hip Replacement 3Health News:Baptist Health and Jacksonville Orthopaedic Institute Offering MAKOplasty® Total Hip Replacement 4Health News:TMG Health Recognized by the Business Continuity Institute 2Health News:TMG Health Recognized by the Business Continuity Institute 3
... go before they can claim to be new generation daddies, for only ... to a survey. ,The UK survey noted that 75 ... and 16 percent men argue every time over the issue. ... men argue about the job, it might help the couple to grow ...
... (RA) face different treatment options and determining which ones ... examined patients decisions regarding therapy for RA and glucosamine ... reluctant to change their treatment as long as their ... clinical trial results for glucosamine. ,Recent advances ...
... ability to walk. He and his mother feared that within ... a wheelchair. ,As is the case with more ... with few options and his family turned to Hospital for ... address his condition. ,They were introduced to David ...
... N.J., The European Commission granted marketing authorization ... atypical antipsychotic medication for the treatment ... designed to deliver paliperidone - the active ... osmotic delivery system (OROS(R)). ,In ...
... how gender affects learning have found that boys and ... different ways. ,However, they have suggested ... their kids from co-educational to segregated schools, or vice-versa. ... at Newcastle University in NSW, said that the key ...
... Scientists have achieved the first success in "decrypting" an enzyme's ... efficient route to drug discovery. ,Led by ... of Medicine, and Frank Raushel of Texas A and M, ... drug discovery, as many of the most successful drugs work ...
Cached Medicine News:Health News:Alternative Treatments for Arthritis 2Health News:Alternative Treatments for Arthritis 3Health News:Motion Analysis Helps Teen With Cerebral Palsy Regain Ability to Walk 2Health News:Motion Analysis Helps Teen With Cerebral Palsy Regain Ability to Walk 3Health News:INVEGA(TM) Gets Marketing Authority from EU to Treat Schizophrenia 2Health News:INVEGA(TM) Gets Marketing Authority from EU to Treat Schizophrenia 3Health News:Boys and Girls are Different by Nature and Learn in Different Ways 2Health News:"Decryption" of Enzyme's Functions Paves Way for Future Drug Discovery 2
... and powerful Parisian Peel ESPRIT system encompasses ... for simplified skin care practice. , The ... meet strict medical device standards while offering ... a compact design. The ESPRIT offers ...
... high resolution optical coherence tonometry (OCT) retina ... It is based on the ... emerging from clinical research in the last ... and high resolution features enable the FD-OCT ...
For the qualitative detection of IgG/IgM antibodies to B. burgdorferi...
The Clearview hCG Test is for the rapid detection of human chorionic gonadotropin (hCG) in urine specimens. This test kit is used to obtain a visual, qualitative result and is intended for professio...
Medicine Products: